Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan

Gynuity Health Projects

Status: Completed

Conditions: Abortion in Second Trimester

Study type: Observational

Funder types: Other

Identifiers

NCT02235155

1017

Details and patient eligibility

About

The primary goal is to examine the efficacy and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Uzbekistan.

Enrollment: 135 patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Meet legal criteria to obtain abortion
• Have an ongoing pregnancy of 13-22 weeks gestation
• Be willing to undergo a surgical completion if necessary
• Have no contraindications to study procedures, according to provider
• Be willing and able to consent to procedure, either by reading consent document or by having consent document read to her
• Be willing to follow study procedures

Exclusion criteria

• Known previous transmural uterine incision
• Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
• Any contraindications to vaginal delivery, including placenta previa

Trial design

135 participants in 1 patient group

Pregnant women of 13-22 weeks gestation

Description:

Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.